Treatment with Abrocitinib utilizing either induction with 200 mg Abrocitinib followed by maintenance with reduced-dose 100 mg Abrocitinib or continuous dosing with 200 mg Abrocitinib is an efficient and well-tolerated therapeutic strategy in atopic dermatitis-affected people, as deciphered from the post-hoc analysis of phase 3 JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN trial.

Researchers wanted to assess how well people responded to therapy reintroduction following flare, withdrawal, or continuous/reduced-dose Abrocitinib. Adults and adolescents (12–17 years old) with moderate-severe atopic dermatitis responding to 200–mg Abrocitinib induction received either placebo or Abrocitinib (200 mg/100 mg) for 40 weeks of maintenance. Rescue care was given to subjects who flared up while on maintenance.

As found, 655/981 (66.8%) and 145/246 (58.9%) of the 981 adults and 246 adolescents, respectively, responded to induction. The flare occurred during maintenance with 200 mg Abrocitinib (14.9%/16.9%), 100 mg Abrocitinib (42.9%/38.9%), and placebo (75.5%/78.0%) in comparable amounts in both adults and adolescents. Eczema Area and Severity Index (EASI) responses were recaptured by about 28.6%, 25.0%, and 52.9% of adolescents and 34.3%, 33.7%, and 58.0% of adults for the Abrocitinib 200-mg, 100-mg, and placebo groups, respectively.

The Investigator's Global Assessment (IGA) responses were recaptured by 42.9%, 50.0%, and 73.5% of adolescents and 34.3%, 50.6%, and 74.1% of adults. Regardless of age, Abrocitinib exhibited a comparable safety profile; nausea occurrence was greater in adolescents. For both adults and adolescents, Abrocitinib proved helpful in preventing flares.